Literature DB >> 2487536

Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: comparison with verapamil.

R Ferrari1, R Raddino, C Ceconi, S Curello, S Ghielmi, O Visioli.   

Abstract

To assess whether pretreatment with the calcium antagonist anipamil protects the heart against ischemic and reperfusion damage and to establish how long the protection persists after cessation of the therapy, rabbits were injected subcutaneously twice daily for 5 days with 2 mg/kg body weight of this drug. The heart was then isolated 2, 6, or 12 hours after the last injection and was perfused by the Langendorff technique during a control period and 90 minutes of total ischemia (37 degrees C), followed by 30 minutes of reperfusion. Diastolic and developed pressure was monitored; coronary effluent was collected and assayed for creatine phosphokinase (CPK); mitochondria were harvested and assayed for respiratory activity, ATP production, and calcium content; and tissue concentration of adenosine triphosphate (ATP) and creatine phosphate were determined. The data obtained with anipamil were compared with those obtained with verapamil administered to the rabbit at the same dose and following the same procedure. Pretreatment with anipamil induced a negative inotropic effect under normoxic conditions; reduced the rate and extent of depletion of ATP and creatine phosphate during ischemia, with an incomplete restoration of the nucleotides after reperfusion; maintained mitochondrial function and calcium homeostasis during ischemia and reperfusion; reduced the rate of CPK release; and improved the recovery of ventricular function on reperfusion. The protective effects of anipamil persisted for as long as 12 hours after the last administration. In contrast, the protective and negative inotropic effects of verapamil were no longer apparent in heart isolated 6 or 12 hours after the last dose of the drug.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2487536     DOI: 10.1007/bf01858111

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  36 in total

1.  Abnormal mitochondrial oxidative phosphorylation of ischemic myocardium reversed by Ca2+-chelating agents.

Authors:  C F Peng; J J Kane; M L Murphy; K D Straub
Journal:  J Mol Cell Cardiol       Date:  1977-11       Impact factor: 5.000

Review 2.  Regulation of glycolysis in the ischemic and the anoxic myocardium.

Authors:  W Kübler; P G Spieckermann
Journal:  J Mol Cell Cardiol       Date:  1970-12       Impact factor: 5.000

3.  Protection of infarcting myocardium by slow channel inhibitors. Comparative effects of verapamil, nifedipine, and diltiazem in the coronary-ligated, isolated working rat heart.

Authors:  C W Hamm; L H Opie
Journal:  Circ Res       Date:  1983-02       Impact factor: 17.367

4.  Protective effect of pretreatment with the calcium antagonist anipamil on the ischemic-reperfused rat myocardium: a phosphorus-31 nuclear magnetic resonance study.

Authors:  J H Kirkels; T J Ruigrok; C J Van Echteld; F L Meijler
Journal:  J Am Coll Cardiol       Date:  1988-05       Impact factor: 24.094

5.  Effect of intracoronary verapamil on infarct size in the ischemic, reperfused canine heart: critical importance of the timing of treatment.

Authors:  H M Lo; R A Kloner; E Braunwald
Journal:  Am J Cardiol       Date:  1985-10-01       Impact factor: 2.778

6.  The effect of two different diltiazem treatments on infarct size in ischemic, reperfused porcine hearts.

Authors:  H H Klein; M Schubothe; K Nebendahl; H Kreuzer
Journal:  Circulation       Date:  1984-05       Impact factor: 29.690

7.  Oxygen-mediated myocardial damage during ischaemia and reperfusion: role of the cellular defences against oxygen toxicity.

Authors:  R Ferrari; C Ceconi; S Curello; C Guarnieri; C M Caldarera; A Albertini; O Visioli
Journal:  J Mol Cell Cardiol       Date:  1985-10       Impact factor: 5.000

8.  Protective effect of early and late treatment with nifedipine during myocardial infarction in the conscious dog.

Authors:  J A Melin; L C Becker; G M Hutchins
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

9.  Cardioprotective actions of a new calcium channel blocker in acute myocardial ischemia.

Authors:  M E Brezinski; H Darius; A M Lefer
Journal:  Arzneimittelforschung       Date:  1986-03

Review 10.  Fundamental mechanisms of action of calcium antagonists in myocardial ischemia.

Authors:  W G Nayler; S Panagiotopoulos; J S Elz; W J Sturrock
Journal:  Am J Cardiol       Date:  1987-01-30       Impact factor: 2.778

View more
  6 in total

1.  Effect of propionyl-L-carnitine on mechanical function of isolated rabbit heart.

Authors:  R Ferrari; E Pasini; E Condorelli; A Boraso; R Lisciani; A Marzo; O Visiou
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

Review 2.  Protective effects of calcium antagonists against ischaemia and reperfusion damage.

Authors:  R Ferrari; O Visioli
Journal:  Drugs       Date:  1991       Impact factor: 9.546

3.  Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil.

Authors:  R Raddino; E Poli; E Pasini; R Ferrari
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

4.  Beneficial actions of amlodipine in the multiple-stunned canine myocardium.

Authors:  G J Gross; G M Pieper
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 5.  How do calcium antagonists differ in clinical practice?

Authors:  R Ferrari; F Cucchini; R Bolognesi; T Bachetti; A Boraso; P Bernocchi; G Gaia; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

6.  Anipamil prevents ST depression in patients with stable angina pectoris.

Authors:  C T Larsen; C Sørum; V Rasmussen; J Fischer Hansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.